Workiva Signs OEM Agreement with SAP to Offer SAP® Cloud Platform Integration with the Workiva Wdesk Platform
Workiva (NYSE:WK), a leader in cloud-based data collaboration, reporting and compliance solutions, today announced it has signed an original equipment manufacturer (OEM) agreement with SAP (NYSE:SAP).
Through this agreement, Workiva is partnering with SAP to provide a first-party integration with the Wdesk platform using the SAP® Cloud Platform Integration service. The bundled solutions are expected to provide customers with powerful linking, auditability and control features.
“Today’s announcement demonstrates that Workiva and SAP are committed to providing customers with a rich integration experience,” said Matt Rizai, chairman and CEO of Workiva. “Through our OEM partnership, we will help customers all over the world improve the value of their business data.”
After users integrate their SAP business data directly into the Wdesk platform, they can benefit from the full capabilities of Wdesk, including synchronized data, dynamic commentary, controlled collaboration, granular permissions and clear audit trails. Wdesk enables narrative to be linked to data across documents, spreadsheets, presentations and reports.
Customers will be able to rely on the data transparency and consistency that Wdesk provides to help mitigate risk and have confidence in their data-driven decisions.
“SAP customers across every industry are looking to leverage cloud technology to improve data collaboration, reduce costs and gain greater business insights,” said Diane Fanelli, senior vice president, Platform Channels at SAP. “Our partnership with Workiva will help our customers improve data integrity and drive better business performance.”
About Workiva
Workiva delivers Wdesk, a leading enterprise cloud platform for data collaboration, reporting and compliance that is used by thousands of organizations worldwide, including over 70 percent of the Fortune 500®. Companies of all sizes, state and local governments and educational institutions use Wdesk to help mitigate risk, improve productivity and gain confidence in their data-driven decisions. For more information about Workiva (NYSE:WK), please visit workiva.com.
Read the Workiva blog: www.workiva.com/blog
Follow
Workiva on LinkedIn: www.linkedin.com/company/workiva
Like
Workiva on Facebook: www.facebook.com/workiva/
Follow
Workiva on Twitter: www.twitter.com/Workiva
Claim not confirmed by FORTUNE or TIME INC. FORTUNE® and FORTUNE 500® are registered trademarks of Time Inc. and are used under license. FORTUNE and Time Inc. are not affiliated with, and do not endorse products or services of, Workiva Inc.
Workiva Safe Harbor Statement
Certain statements in this
press release are “forward-looking statements” within the meaning of
Section 21E of the Securities Exchange Act of 1934, as amended, and are
subject to the safe harbor created thereby. These statements relate to
future events or Workiva’s future financial performance and involve
known and unknown risks, uncertainties and other factors that may cause
the actual results, levels of activity, performance or achievements of
Workiva or its industry to be materially different from those expressed
or implied by any forward-looking statements. In particular, statements
about Workiva’s expectations, beliefs, plans, objectives, assumptions,
future events or future performance contained in this press release are
forward-looking statements. In some cases, forward-looking statements
can be identified by terminology such as “may,” “will,” “could,”
“would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,”
“estimate,” “predict,” “potential,” “outlook,” “guidance” or the
negative of those terms or other comparable terminology. Please see
Workiva’s documents filed or to be filed with the Securities and
Exchange Commission, including the Workiva’s annual reports filed on
Form 10-K and quarterly reports on Form 10-Q, and any amendments thereto
for a discussion of certain important risk factors that relate to
forward-looking statements contained in this report. Workiva has based
these forward-looking statements on its current expectations,
assumptions, estimates and projections. While Workiva believes these
expectations, assumptions, estimates and projections are reasonable,
such forward-looking statements are only predictions and involve known
and unknown risks and uncertainties, many of which are beyond Workiva’s
control. These and other important factors may cause actual results,
performance or achievements to differ materially from those expressed or
implied by these forward-looking statements. Any forward-looking
statements are made only as of the date hereof, and unless otherwise
required by applicable securities laws, Workiva disclaims any intention
or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
SAP and other SAP products and services mentioned herein as well as their respective logos are trademarks or registered trademarks of SAP SE (or an SAP affiliate company) in Germany and other countries. See www.sap.com/corporate-en/legal/copyright/index.epx for additional trademark information and notices. All other product and service names mentioned are the trademarks of their respective companies.
SAP Forward-looking Statement
Any statements contained in
this document that are not historical facts are forward-looking
statements as defined in the U.S. Private Securities Litigation Reform
Act of 1995. Words such as “anticipate,” “believe,” “estimate,”
“expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,”
“should” and “will” and similar expressions as they relate to SAP are
intended to identify such forward-looking statements. SAP undertakes no
obligation to publicly update or revise any forward-looking statements.
All forward-looking statements are subject to various risks and
uncertainties that could cause actual results to differ materially from
expectations The factors that could affect SAP's future financial
results are discussed more fully in SAP's filings with the U.S.
Securities and Exchange Commission ("SEC"), including SAP's most recent
Annual Report on Form 20-F filed with the SEC. Readers are cautioned not
to place undue reliance on these forward-looking statements, which speak
only as of their dates.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180524005409/en/
Contact information
Workiva Inc.
Kevin McCarthy, 515-663-4471
press@workiva.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 02:09:00 CEST | Press release
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines,today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio har
HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release
HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com